FR18C1008I2 - Regime posologique de cladribine pour le traitement de la sclerose en plaques - Google Patents
Regime posologique de cladribine pour le traitement de la sclerose en plaquesInfo
- Publication number
- FR18C1008I2 FR18C1008I2 FR18C1008C FR18C1008C FR18C1008I2 FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2 FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2
- Authority
- FR
- France
- Prior art keywords
- cladribine
- treatment
- multiple sclerosis
- dosage regimen
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title 1
- 229960002436 cladribine Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| PCT/EP2005/056954 WO2006067141A1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
| EP05823474A EP1827461B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR18C1008I1 FR18C1008I1 (enrdf_load_stackoverflow) | 2018-03-30 |
| FR18C1008I2 true FR18C1008I2 (fr) | 2019-03-01 |
Family
ID=36227798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR18C1008C Active FR18C1008I2 (fr) | 2004-12-22 | 2018-02-14 | Regime posologique de cladribine pour le traitement de la sclerose en plaques |
Country Status (25)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1827461T3 (pl) | 2004-12-22 | 2012-07-31 | Merck Serono Sa | Schemat podawania kladrybiny w leczeniu stwardnienia rozsianego |
| AU2007253254B2 (en) | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| BR112020010282A2 (pt) * | 2017-11-24 | 2020-11-17 | Merck Patent Gmbh | regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla |
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| DE69528080T2 (de) | 1994-12-22 | 2003-06-05 | Ortho Pharma Corp | Lösliche arzneizusammensetzungen enthaltend 2-chloro-2'-deoxyadenosine |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| CA2540158C (en) | 2002-09-25 | 2011-07-05 | Morris J. Robins | Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| EA010801B1 (ru) * | 2003-02-25 | 2008-12-30 | Лаборатуар Сероно Са | Комбинированное применение рибавирина и бета-интерферона при демиелинизирующих заболеваниях |
| EA009714B1 (ru) | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки |
| RS20050735A (en) * | 2003-03-28 | 2008-06-05 | Ares Trading S.A., | Cladribine formulations for improved oral and transmucosal delivery |
| PL1827461T3 (pl) | 2004-12-22 | 2012-07-31 | Merck Serono Sa | Schemat podawania kladrybiny w leczeniu stwardnienia rozsianego |
| AU2007253254B2 (en) * | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en active Pending
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es active Active
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en active Active
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja active Active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es active Active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR18C1008I2 (fr) | Regime posologique de cladribine pour le traitement de la sclerose en plaques | |
| FR23C1003I1 (fr) | Compositions et leurs utilisations pour le traitement de la Sclérose en plaques | |
| EP1931691A4 (en) | ODKASE INHIBITORS FOR THE TREATMENT OF MALARIA | |
| EP1838320A4 (en) | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS | |
| EP1951272A4 (en) | USE OF LACTOBACILLUS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| EP1985302A4 (en) | DRUGS FOR TUMOR THERAPY AND ITS USE | |
| EP2773643A4 (en) | PAK HEMMER FOR TREATING FRAGILEM X SYNDROME | |
| EP2643018A4 (en) | ANTI-IL-6 ANTIBODY FOR THE TREATMENT OF MUNICHCHLEIMHAUTENZÜNDUNGEN | |
| EP2043630A4 (en) | 6, 9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE FOR SKIN TREATMENT | |
| EP2154971A4 (en) | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | |
| FR2907011B1 (fr) | Utilisation de la citrulline pour le traitement des etats de denutrition | |
| MA29097B1 (fr) | Composes pour le traitement des infections virales par flaviviridae | |
| PL2205720T3 (pl) | Kompozycja do leczenia stwardnienia rozsianego | |
| EP2144632A4 (en) | SYNTHETIC HERPES SIMPLEX VIRUS TYPE 1 FOR TUMOR TREATMENT | |
| EP1789069A4 (en) | CYCLIC PEPTIDES FOR THE TREATMENT OF CACHEXIA | |
| FR2962041B1 (fr) | Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies | |
| EP1773970A4 (en) | LUBRICANT FORMULATIONS FOR PANEL PROCESSING | |
| EP1732549A4 (en) | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES | |
| FR2910813B1 (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| FR2886153B1 (fr) | Composition destinee au traitement de la sclerose en plaques | |
| EP2099303A4 (en) | THERAPEUTIC COMPOSITIONS ON TETRAHYDROISOCHINOLINE BASE FOR CANCER THERAPY | |
| FR2901703B1 (fr) | Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques | |
| FR2875404B1 (fr) | Composition pharmaceutique pour le traitement de la rosacee | |
| FR2915099B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| EP2077114A4 (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF FIBROMYALGIA |